Chartwell Investment Partners LLC Acquires 246,594 Shares of Haleon plc (NYSE:HLN)

Chartwell Investment Partners LLC increased its position in shares of Haleon plc (NYSE:HLN) by 107.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 475,415 shares of the company’s stock after acquiring an additional 246,594 shares during the period. Chartwell Investment Partners LLC’s holdings in Haleon were worth $5,030,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Crossmark Global Holdings Inc. lifted its holdings in shares of Haleon by 55.6% during the third quarter. Crossmark Global Holdings Inc. now owns 480,760 shares of the company’s stock worth $5,087,000 after purchasing an additional 171,877 shares during the period. Axxcess Wealth Management LLC boosted its holdings in Haleon by 2.3% during the third quarter. Axxcess Wealth Management LLC now owns 63,843 shares of the company’s stock worth $675,000 after purchasing an additional 1,450 shares during the last quarter. Portside Wealth Group LLC boosted its stake in Haleon by 4.5% in the third quarter. Portside Wealth Group LLC now owns 47,003 shares of the company’s stock valued at $497,000 after acquiring an additional 2,018 shares during the last quarter. PDS Planning Inc boosted its stake in Haleon by 17.5% in the third quarter. PDS Planning Inc now owns 16,409 shares of the company’s stock valued at $174,000 after acquiring an additional 2,443 shares during the last quarter. Finally, QRG Capital Management Inc. raised its position in shares of Haleon by 20.9% in the third quarter. QRG Capital Management Inc. now owns 201,934 shares of the company’s stock valued at $2,136,000 after purchasing an additional 34,884 shares during the period. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Trading Down 1.0 %

NYSE HLN opened at $9.51 on Tuesday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a 12 month low of $7.89 and a 12 month high of $10.80. The company’s 50-day moving average price is $10.18 and its 200-day moving average price is $9.32. The stock has a market cap of $43.05 billion, a PE ratio of 27.97, a PEG ratio of 2.90 and a beta of 0.30.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. UBS Group raised shares of Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. The Goldman Sachs Group cut shares of Haleon from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. Morgan Stanley lifted their price target on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research note on Friday, September 20th. Finally, Berenberg Bank assumed coverage on shares of Haleon in a research report on Tuesday, August 6th. They set a “buy” rating for the company. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.